Irisin attenuates inflammation in a mouse model of ulcerative colitis by altering the intestinal microbiota

Huangfu,Lu Xin; Cai,Xin Tong; Yang,Jing Nan; Wang,Hui Chao; Li,Yu Xia; Dai,Zhi Feng; Yang,Rui Lin; Lin,Xu Hong

doi:10.3892/etm.2021.10868

Irisin attenuates inflammation in a mouse model of ulcerative colitis by altering the intestinal microbiota

Authors:
- Lu Xin Huangfu
- Xin Tong Cai
- Jing Nan Yang
- Hui Chao Wang
- Yu Xia Li
- Zhi Feng Dai
- Rui Lin Yang
- Xu Hong Lin
View Affiliations

Affiliations: Department of Gastroenterology, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, P.R. China, Department of Pathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Department of Clinical Laboratory, Translational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, P.R. China, Department of Nephrology, The First Affiliated Hospital of Henan University, Kaifeng, Henan 475000, P.R. China, Department of Clinical Laboratory, Translational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, P.R. China
Published online on: October 11, 2021 https://doi.org/10.3892/etm.2021.10868
Article Number: 1433
Copyright: © Huangfu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Evidence has demonstrated that the gut microbiota, which consists of probiotics and pathogenic microorganisms, is involved in the initiation of ulcerative colitis (UC) via the dysregulation of intestinal microflora and normal immune interactions, which ultimately leads to intestinal mucosal dysfunction. Irisin is released from muscle cells and displays anti‑inflammatory effects; however, the mechanisms underlying irisin‑mediated anti‑inflammatory effects in UC have not been previously reported. In the present study, mice were divided into the following four groups: i) Control; ii) irisin; iii) dextran sulfate sodium (DSS) salt; and iv) DSS + irisin. Subsequently, the effects of irisin were investigated by observing alterations in intestinal microbes. Irisin significantly reduced the degree of inflammation in UC by reversing alterations to the macroscopic score, histological score, number of CD64+ cells and inflammatory cytokine alterations (P<0.05). Analysis of the microbial diversity in the stools of mice with active UC indicated that the five bacteria that displayed the greatest alterations in relative abundance were Alloprevotella, Bacteroides, Lachnospiraceae‑UCG‑001, Prebotellaceae‑UCG‑001 and Rikenellaceae‑RCB‑gut‑group. Furthermore, Bactoroides were positively correlated with the histopathological score (P=0.001; R=0.977) and interleukin (IL)‑23 levels (P=0.008; R=0.924). Alloprevotella (P=0.001; R=‑0.943), Lachnospiraceae‑UCG‑001 (P=0.000; R=‑0.973) and Rikenollaceae‑RC8‑gut‑group (P=0.001; R=‑0.971) were negatively correlated with the histopathological score. Furthermore, Lachnospiraceae‑UCG‑001 (P=0.01; R=‑0.873) and Rikenollaceae‑RC8‑gut‑group (P=0.049; R=‑0.814) were negatively correlated with IL‑23 levels. In summary, the results of the present study suggested that irisin improved inflammation in a UC mouse model potentially via altering the gut microbiota.

View Figures

View References

1	Anzai H, Hata K, Kishikawa J, Ishii H, Yasuda K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, et al: Appendiceal orifice inflammation is associated with proximal extension of disease in patients with ulcerative colitis. Colorectal Dis. 18:0278–0282. 2016.PubMed/NCBI View Article : Google Scholar
2	Podolsky DK: Inflammatory bowel disease. N Engl J Med. 347:417–429. 2002.PubMed/NCBI View Article : Google Scholar
3	Grinspan A and Kornbluth A: Positioning therapy for ulcerative colitis. Curr Gastroenterol. 17(29)2015.PubMed/NCBI View Article : Google Scholar
4	Khor B, Gardet A and Xavier RJ: Genetics and pathogenesis of inflammatory bowel disease. Nature. 474:307–317. 2011.PubMed/NCBI View Article : Google Scholar
5	Legaki E and Gazouli M: Influence of environmental factors in the development of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther. 7:112–125. 2016.PubMed/NCBI View Article : Google Scholar
6	Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N and Pace NR: Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 104:13780–13785. 2007.PubMed/NCBI View Article : Google Scholar
7	Ihara S, Hirata Y and Koike K: TGF-β in inflammatory bowel disease: A key regulator of immune cells, epithelium, and the intestinal microbiota. J Gastroenterol. 52:777–787. 2017.PubMed/NCBI View Article : Google Scholar
8	Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, et al: Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 55:205–211. 2006.PubMed/NCBI View Article : Google Scholar
9	Schwab C, Berry D, Rauch I, Rennisch I, Ramesmayer J, Hainzl E, Heider S, Decker T, Kenner L, Muller M, et al: Longitudinal study of murine microbiota activity and interactions with the host during acute inflammation and recovery. ISME J. 8:1101–1114. 2014.PubMed/NCBI View Article : Google Scholar
10	Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, et al: A PGC1-alphadependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 481:463–468. 2012.PubMed/NCBI View Article : Google Scholar
11	Yi Z, Yi S and Shu-Zhe D: The novel Myokine-Irisin. Chin J Biochem Mol Biol. 33:429–435. 2017.
12	Farmer SR: Boning up on Irisin. N Engl J Med. 380:1480–1482. 2019.PubMed/NCBI View Article : Google Scholar
13	Mahgoub MO, D'Souza C, Al Darmaki RSMH, Baniyas MMYH and Adeghate E: An update on the role of irisin in the regulation of endocrine and metabolic functions. Peptides. 104:15–23. 2018.PubMed/NCBI View Article : Google Scholar
14	Buscemi S, Corleo D, Vasto S, Buscemi C, Barile AM, Rosafio G, Randazzo C, Currenti W and Galvano F: Serum Irisin concentrations in severely inflamed patients. Horm Metab Res. 52:246–250. 2020.PubMed/NCBI View Article : Google Scholar
15	Mazur-Bialy AI: Superiority of the Non-glycosylated form over the glycosylated form of Irisin in the attenuation of adipocytic meta-inflammation: A potential factor in the fight against insulin resistance. Biomolecules. 9(394)2019.PubMed/NCBI View Article : Google Scholar
16	Mazur-Bialy AI, Pocheć E and Zarawski M: Anti-inflammatory properties of Irisin, mediator of physical activity, are connected with TLR4/MyD88 signaling pathway activation. Int J Mol Sci. 18:701–712. 2017.PubMed/NCBI View Article : Google Scholar
17	Shao L, Meng D, Yang F, Haibo S and Dongqi T: Irisin-mediated protective effect on LPS-induced acute lung injury via suppressing inflammation and apoptosis of alveolar epithelial cells. Biochem Biophys Res Commun. 487:194–200. 2017.PubMed/NCBI View Article : Google Scholar
18	Mazur-Bialy AI, Bilski J, Wojcik D, Brzozowski B, Surmiak M, Hubalewska-Mazgaj M, Chmura A, Magierowski M, Magierowska K, Mach T and Brzozowski T: Beneficial effect of voluntary exercise on experimental colitis in mice fed a High-Fat Diet: The role of Irisin, adiponectin and proinflammatory biomarkers. Nutrients. 9(410)2017.PubMed/NCBI View Article : Google Scholar
19	Asadi Y, Gorjipour F, Behrouzifar S and Vakili A: Irisin peptide protects brain against ischemic injury through reducing apoptosis and enhancing BDNF in a rodent model of stroke. Neurochem Res. 43:1549–1560. 2018.PubMed/NCBI View Article : Google Scholar
20	Pitts M: Applied Research Ethics National Association/Office of Laboratory Animal Welfare. Institutional Animal Care and Use Committee. A Guide to the New ARENA/OLAW IACUC Guidebook. Lab Anim (NY). 31:40–42. 2002.PubMed/NCBI View Article : Google Scholar
21	Siegmund B, Lehr HA, Fantuzzi G and Dinarello CA: IL-1β-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA. 98:13249–13254. 2001.PubMed/NCBI View Article : Google Scholar
22	Murano M, Maemura K, Hirata I, Toshina K, Nishikawa T, Hamamoto N, Sasaki S, Saitoh O and Katsu K: Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol. 120:51–58. 2000.PubMed/NCBI View Article : Google Scholar
23	Jumpstart Consortium Human Microbiome Project Data Generation Working Group. Evaluation of 16S rDNA-based community profiling for human microbiome research. PLoS One. 7(e39315)2012.PubMed/NCBI View Article : Google Scholar
24	Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, et al: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 390:2769–2778. 2018.PubMed/NCBI View Article : Google Scholar
25	Porter RJ, Kalla R and Ho GT: Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Res. 9(F1000)2020.PubMed/NCBI View Article : Google Scholar
26	Colquhoun C, Duncan M and Grant G: Inflammatory bowel diseases: Host-microbial-environmental interactions in dysbiosis. Diseases. 8(E13)2020.PubMed/NCBI View Article : Google Scholar
27	Kaser A, Zeissig S and Blumberg RS: Inflammatory bowel disease. Annu Rev Immunol. 28:573–621. 2010.PubMed/NCBI View Article : Google Scholar
28	Martini E, Krug SM, Siegmund B, Neurath MF and Becker C: Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 4:33–46. 2017.PubMed/NCBI View Article : Google Scholar
29	Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al: A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 464:59–65. 2010.PubMed/NCBI View Article : Google Scholar
30	Etienne-Mesmin L, Chassaing B, Desvaux M, De Paepe K, Gresse R, Sauvaitre T, Forano E, de Wiele TV, Schüller S, Juge N and Blanquet-Diot S: Experimental models to study intestinal microbes-mucus interactions in health and disease. FEMS Microbiol Rev. 43:457–489. 2019.PubMed/NCBI View Article : Google Scholar
31	O'Callaghan AA and Corr SC: Establishing boundaries: The relationship that exists between intestinal epithelial cells and gut-dwelling bacteria. Microorganisms 7: Efficiency of cancer therapy. Front Microbiol. 10(1050)2019.PubMed/NCBI View Article : Google Scholar
32	Ma W, Mao Q, Xia W, Dong G, Yu C and Jiang F: Gut microbiota shapes the efficiency of cancer therapy. Front Microbiol. 10(1050)2019.PubMed/NCBI View Article : Google Scholar
33	Mika A, Van Treuren W, González A, Herrera JJ, Knight R and Fleshner M: Exercise is more effective at altering gut microbial composition and producing stable changes in lean mass in juvenile versus adult male F344 rats. PLoS One. 10(e0125889)2015.PubMed/NCBI View Article : Google Scholar
34	Mohr AE, Jäger R, Carpenter KC, Kerksick CM, Purpura M, Townsend JR, West NP, Black K, Gleeson M, Pyne DB, et al: The athletic gut microbiota. J Int Soc Sports Nutr. 17(24)2020.PubMed/NCBI View Article : Google Scholar
35	Luo B, Xiang D, Nieman DC and Chen P: The effects of moderate exercise on chronic stress-induced intestinal barrier dysfunction and antimicrobial defense. Brain Behav Immunity. 39:99–106. 2014.PubMed/NCBI View Article : Google Scholar
36	Clarke SF, Murphy EF, O'Sullivan O, Lucey AJ, Humphreys M, Hogan A, Hayes P, O'Reilly M, Jeffery IB, Wood-Martin R, et al: Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 63:1913–1920. 2014.PubMed/NCBI View Article : Google Scholar
37	Allen JM, Berg Miller ME, Pence BD, Whitlock K, Nehra V, Gaskins HR, White BA, Fryer JD and Woods JA: Voluntary and forced exercise differentially alters the gut microbiome in C57BL/6J mice. J Appl Physiol. 118:1059–1066. 2015.PubMed/NCBI View Article : Google Scholar
38	Yang Y, Gang C, Qian Y, Juan Y, Xueting C, Pamo T, Xiaolan C, Chunping H, Shuangquan Z and Peng C: Gut microbiota drives the attenuation of dextran sulphate sodium-induced colitis by Huangqin decoction. Oncotarget. 8:48863–48874. 2017.PubMed/NCBI View Article : Google Scholar
39	Liu JH, Chen ZL, Li Y and Yu DJ: Development of denaturant gradient gel electrophoresis for analysis of intestinal microflora community diversity. Chin J Veterinary Sci Technol. 35:2006.
40	Donaldson GP, Ladinsky MS, Yu KB, Sanders JG, Yoo BB, Chou WC, Conner ME, Earl AM, Knight R, Bjorkman PJ and Mazmanian SK: Gut microbiota utilize immunoglobulin A for mucosal colonization. Science. 360:795–800. 2018.PubMed/NCBI View Article : Google Scholar
41	Moor K, Diard M, Sellin ME, Felmy B, Wotzka SY, Toska A, Bakkeren E, Arnoldini M, Bansept F, Co AD, et al: High-avidity IgA protects the intestine by enchaining growing bacteria. Nature. 544:498–502. 2017.PubMed/NCBI View Article : Google Scholar
42	Frehn L, Jansen A, Bennek E, Mandic AD, Temizel I, Tischendorf S, Verdier J, Tacke F, Streetz K, Trautwein C and Sellge G: Distinct patterns of IgG and IgA against food and microbial antigens in serum and feces of patients with inflammatory bowel diseases. PLoS One. 9(e106750)2014.PubMed/NCBI View Article : Google Scholar
43	Kurashima Y and Kiyono H: Mucosal ecological network of epithelium and immune cells for gut homeostasis and tissue healing. Annu Rev Immunol. 35:119–147. 2017.PubMed/NCBI View Article : Google Scholar
44	Pei LY, Ke YS, Zhao HH, Wang L, Jia C, Liu WZ, Fu QH, Shi MN, Cui J and Li SC: Role of colonic microbiota in the pathogenesis of ulcerative colitis. BMC Gastroenterol. 19(10)2019.PubMed/NCBI View Article : Google Scholar
45	Li X, Jamal M, Guo P, Jin Z, Zheng F, Song X, Zhan J and Wu H: Irisin alleviates pulmonary epithelial barrier dysfunction in sepsis-induced acute lung injury via activation of AMPK/SIRT1 pathways. Biomed Pharmacother. 118(109363)2019.PubMed/NCBI View Article : Google Scholar
46	Chen K, Xu Z, Liu Y, Wang Z, Li Y, Xu X, Chen C, Xia T, Liao Q, Yao Y, et al: Irisin protects mitochondria function during pulmonary ischemia/reperfusion injury. Sci Transl Med. 9(eaao6298)2017.PubMed/NCBI View Article : Google Scholar
47	Narayanan SA, Metzger CE, Bloomfield SA and Zawieja DC: Inflammation-induced lymphatic architecture and bone turnover changes are ameliorated by Irisin treatment in chronic inflammatory bowel disease. FASEB J. 32:4848–4861. 2018.PubMed/NCBI View Article : Google Scholar
48	Murphy KM, Ouyang W and Farrar JD: Signaling and transcription in T helper development. Annu Rev Immunol. 18:451–494. 2000.PubMed/NCBI View Article : Google Scholar
49	Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL and Heller F: Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inlamm Bowel Dis. 12:9–15. 2006.PubMed/NCBI View Article : Google Scholar
50	Grivennikov DI, Wang K, Mucida D, Wtewart C, Schnabl B and Jauch D: Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumor growth. Nature. 491:254–258. 2012.PubMed/NCBI View Article : Google Scholar
51	Wang BY, Liu FL, Hu Z, Yu CH, Xia XT, Fan JY and Li X: Effects of Tongxieyaofang on serum levels of interleukin-12 and neuropeptide Y in rats with ulcerative colitis. Hun J Traditional Chin Med. 32:166–167. 2016.
52	Fiorino G, Allocca M, Correale C, Roda G, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L and Danese S: Positioning ustekinumab in moderate-to-severe ulcerative colitis: New kid on the block. Expert Opin Biol Ther. 20:421–427. 2020.PubMed/NCBI View Article : Google Scholar
53	Beaudoin M, Goyette P, Boucher G, Lo KS, Rivas MA, Stevens C, Alikashani A, Ladouceur M, Ellinghaus D, Törkvist L, et al: Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet. 9(e1003723)2013.PubMed/NCBI View Article : Google Scholar
54	Bianchi E and Rogge L: The IL-23/IL-17 pathway in human chronic inflammatory diseases-new insight from genetics and targeted therapies. Microbes Infect. 21:246–253. 2019.PubMed/NCBI View Article : Google Scholar
55	Niederreiter L, Adolph TE and Kaser A: Anti-IL-12/23 in Crohn's disease: Bench and bedside. Curr Drug Targets. 14:1379–1384. 2013.PubMed/NCBI View Article : Google Scholar
56	Eichele DD and Kharbanda KK: Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J Gastroenterol. 23:6016–6029. 2017.PubMed/NCBI View Article : Google Scholar
57	Chassaing B, Aitken JD, Malleshappa M and Vijay-Kumar M: Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol. 104:15.25.1–15.25.14. 2014.PubMed/NCBI View Article : Google Scholar
58	Shimizu T, Suzuki M, Fujimura J, Hisada K, Yoshikazu O, Obinata K and Yamashiro Y: The relationship between the concentration of dextran sodium sulfate and the degree of induced experimental colitis in weanling rats. Pediatr Gastroenterol Nutr. 37:481–486. 2003.PubMed/NCBI View Article : Google Scholar
59	Axelsson LG, Landström E, Goldschmidt TJ, Grönberg A and Bylund-Fellenius AC: Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: Effects in CD4(+) -cell depleted, athymic and NK-cell depleted SCID mice. Inflamm Res. 45:181–191. 1996.PubMed/NCBI View Article : Google Scholar
60	Vowinkel T, Kalogeris TJ, Mori M, Krieglstein CF and Granger DN: Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci. 49:556–564. 2004.PubMed/NCBI View Article : Google Scholar
61	Borody TJ, Warren EF, Leis S, Surace R and Ashman O: Treatment of ulcerative colitis using fecal bacteriotherapy. Clin Gastroenterol. 37:42–47. 2003.PubMed/NCBI View Article : Google Scholar
62	Zhang T, Chen Y, Wang Z, Zhou Y, Zhang S, Wang P, Xie S and Jiang B: Changes of fecal flora and its correlation with inflammatory indicators in patients with inflammatory bowel disease. Nan Fang Yi Ke Da Xue Xue Bao. 33:1474–1477. 2013.PubMed/NCBI(In Chinese).